Amsterdam Commodities, UCB, Lanschot: Benelux Equity Preview

The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.

The AEX-Index (AEX) in Amsterdam advanced 6.06, or 1.8 percent, to 349.26. Belgium’s Bel20 Index rose 34.75, or 1.4 percent, to 2,557.71. Luxembourg’s LuxX Index gained 1 percent to 1,413.83.

Dutch stocks:

Amsterdam Commodities NV (ACOMO) : The world’s largest trader of spices said full-year net income rose 47 percent to 15.5 million euros ($21.7 million). Amsterdam Commodities fell 1.9 percent to 10.35 euros.

Van Lanschot NV (LANS) : The oldest independent Dutch bank may report second-half profit excluding some items of 43 million euros, according to the average of three analyst estimates compiled by Bloomberg. Van Lanschot climbed 3.4 percent to 31.55 euros.

Belgian stocks:

International Brachytherapy SA (IBT BB): Eckert & Ziegler AG (EUZ GY), the majority owner of the Belgian maker of tumor- fighting implants, said it has made an approach to buy Theragenics Corp. (TGX US), either directly or through its Belgian unit, for about $74 million in cash. Theragenics’s board rejected the $2.20-a-share offer, Eckert & Ziegler said. International Brachytherapy (IBT) climbed 2.2 percent to 2.85 euros.

TiGenix NV (TIG) : The developer of treatments for damaged joints that plans to merge with Cellerix SA posted a full-year net loss of 15.7 million euros and said it had 5.6 million euros of cash and short-term investments left on Dec. 31. TiGenix was unchanged at 1.31 euros.

UCB SA (UCB) : The maker of the Cimzia arthritis medicine failed to win the backing of advisers to the European Medicines Agency to market Xyrem as a treatment for fibromyalgia, associated with chronic muscle pain and fatigue, in Europe. UCB rose 1.2 percent to 25.96 euros.

To contact the reporters on this story: John Martens in Brussels at jmartens1@bloomberg.net; Jurjen van de Pol in Amsterdam at jvandepol@bloomberg.net

To contact the editors responsible for this story: Angela Cullen at acullen8@bloomberg.net; Craig Stirling at cstirling1@bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.